Novel Cancer Biomarker and Target

OCR Number: OCR 6886

Description:

N6-methyladenine (N6-mA) inhibitors as cancer biomarkers

- N6-mA levels are significantly increased in aggressive forms of cancer, making it a powerful diagnostic marker.

- Dr. Xiao’s lab at Yale is developing chemical inhibitors against methyltransferases and readers of N6-mA and testing these inhibitors in biochemical assays and patient derived xenograft (PDX) mouse models.

- Several lead compounds have been identified. Medicinal chemistry optimization and large scale screen is in progress.

- Intellectual Property: Patent application has been filed


PI: Andrew Xiao

Licensing Contact: Hong Peng
hong.peng@yale.edu

Figure 2 N6-mA in human cancers